FUMAGALLI, Riccardo M., GJERMENI, Diona, OLIVIER, Christoph, GAUCHEL, Nadine, BIEVER, Paul und BARCO, Stefano, 2025. Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial. Freiburg: Universität.
Elsevier - Harvard (with titles)Fumagalli, R.M., Gjermeni, D., Olivier, C., Gauchel, N., Biever, P., Barco, S., 2025. Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial. Universität, Freiburg. https://doi.org/10.1016/j.rpth.2024.102534
American Psychological Association 7th editionFumagalli, R. M., Gjermeni, D., Olivier, C., Gauchel, N., Biever, P., & Barco, S. (ca. 2025). Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial [Cd]. Universität. https://doi.org/10.1016/j.rpth.2024.102534
Springer - Basic (author-date)Fumagalli RM, Gjermeni D, Olivier C, Gauchel N, Biever P, Barco S (2025) Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Fumagalli, Riccardo M./ Gjermeni, Diona/ Olivier, Christoph/ Gauchel, Nadine/ Biever, Paul/ Barco, Stefano, Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial, Freiburg 2025.